Literature DB >> 20012010

IL6 as a mediator of insulin resistance: fat or fiction?

T L Allen1, M A Febbraio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20012010     DOI： 10.1007/s00125-009-1627-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  31 in total

1.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Authors:  J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  How obesity causes diabetes: not a tall tale.

Authors:  Mitchell A Lazar
Journal:  Science       Date:  2005-01-21       Impact factor: 47.728

3.  Interleukin-6 induces cellular insulin resistance in hepatocytes.

Authors:  Joseph J Senn; Peter J Klover; Irena A Nowak; Robert A Mooney
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

4.  Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.

Authors:  Andrew L Carey; Gregory R Steinberg; S Lance Macaulay; Walter G Thomas; Anna G Holmes; Georg Ramm; Oja Prelovsek; Cordula Hohnen-Behrens; Matthew J Watt; David E James; Bruce E Kemp; Bente K Pedersen; Mark A Febbraio
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

5.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

Authors:  V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

6.  Human IL6 enhances leptin action in mice.

Authors:  M Sadagurski; L Norquay; J Farhang; K D'Aquino; K Copps; M F White
Journal:  Diabetologia       Date:  2009-11-10       Impact factor: 10.122

7.  AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment.

Authors:  Gregory R Steinberg; James W E Rush; David J Dyck
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11-19       Impact factor: 4.310

8.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice.

Authors:  Peter J Klover; Teresa A Zimmers; Leonidas G Koniaris; Robert A Mooney
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

9.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice.

Authors:  S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

10.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.

Authors:  Hyo-Jeong Kim; Takamasa Higashimori; So-Young Park; Hyejeong Choi; Jianying Dong; Yoon-Jung Kim; Hye-Lim Noh; You-Ree Cho; Gary Cline; Young-Bum Kim; Jason K Kim
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461
View more
  14 in total

1.  miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes.

Authors:  Lin Dou; Ting Zhao; Lilin Wang; Xiuqing Huang; Juan Jiao; Dan Gao; Hangxiang Zhang; Tao Shen; Yong Man; Shu Wang; Jian Li
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

2.  Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

Authors:  A D Dobrian; Q Ma; J W Lindsay; K A Leone; K Ma; J Coben; E V Galkina; J L Nadler
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-16       Impact factor: 4.310

3.  IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise.

Authors:  L Fritsche; M Hoene; R Lehmann; H Ellingsgaard; A M Hennige; A K Pohl; H U Häring; E D Schleicher; C Weigert
Journal:  Diabetologia       Date:  2010-04-22       Impact factor: 10.122

4.  Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus.

Authors:  Xiao-Yan Cui; Xiao Wu; Dan Lu; Dan Wang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

Review 5.  The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release.

Authors:  Stephan Wueest; Daniel Konrad
Journal:  Adipocyte       Date:  2018-08-03       Impact factor: 4.534

Review 6.  The role of adipose tissue and adipokines in obesity-related inflammatory diseases.

Authors:  Carmela Rita Balistreri; Calogero Caruso; Giuseppina Candore
Journal:  Mediators Inflamm       Date:  2010-07-01       Impact factor: 4.711

7.  The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity.

Authors:  Zhuo-Xian Meng; Lin Wang; Yuanyuan Xiao; Jiandie D Lin
Journal:  Diabetes       Date:  2014-01-23       Impact factor: 9.461

8.  Role of muscle IL-6 in gender-specific metabolism in mice.

Authors:  Amalia Molinero; Antonio Fernandez-Perez; Aina Mogas; Mercedes Giralt; Gemma Comes; Olaya Fernandez-Gayol; Mario Vallejo; Juan Hidalgo
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

9.  Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-α-induced hepatic insulin resistance.

Authors:  Hongye Zhao; Xiuqing Huang; Juan Jiao; Hangxiang Zhang; Jin Liu; Weiwei Qin; Xiangyu Meng; Tao Shen; Yajun Lin; Jiaojiao Chu; Jian Li
Journal:  Sci Rep       Date:  2015-12-15       Impact factor: 4.379

10.  Susceptibility of brown adipocytes to pro-inflammatory cytokine toxicity and reactive oxygen species.

Authors:  Lars Rebiger; Sigurd Lenzen; Ilir Mehmeti
Journal:  Biosci Rep       Date:  2016-01-21       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.